Bladder Cancer Photodynamic Therapeutic Agent with Off‐On Magnetic Resonance Imaging Enhancement. Issue 11 (16th August 2019)

• Record Type: Journal Article
• Authors: Xie, Chen; Chau, Ho‐Fai; Zhang, Jing‐Xiang; Tong, Sheng; Jiang, Lijun; Fok, Wan‐Yiu; Lung, Hong‐Lok; Zha, Shuai; Zou, Rui; Jiao, Ju; Ng, Chi‐Fai; Ma, Ping'an; Zhang, Junhui; Lin, Jun; Shiu, Kwok Keung; Bünzli, Jean‐Claude G.; Wong, Wai‐Kwok; Long, Nicholas J.; Law, Ga‐Lai; Wong, Ka‐Leung
• Is Part Of: Advanced therapeutics. Volume 2:Issue 11(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-08-16
• Subjects: bladder cancer -- lanthanide -- magnetic resonance imaging -- photodynamic therapy -- porphyrin; Therapeutics -- Periodicals; Pharmaceutical technology -- Periodicals; Pharmacogenetics -- Periodicals; 615.5
• DOI: 10.1002/adtp.201900068
• Languages: English
• ISSNs: 2366-3987

Abstract

Abstract: Acting as an extracellular matrix protein receptor, αV β3 integrin becomes an appealing target for photodynamic therapy of bladder cancer. Here, specific αV β3 ‐integrin‐targeting porphyrinato‐gadolinium complexes (Gd‐PEG‐R n ) are demonstrated as off‐on theranostic agents, where R n are specific peptides. Among them, Gd‐PEG‐R 3 shows both impressive phototherapeutic index and robust in vivo magnetic resonance imaging (MRI) signal enhancement. Significant selectivity of Gd‐PEG‐R 3 is proven by its high αV β3 integrin binding affinity in positive bladder cancer cells. All these findings support Gd‐PEG‐R 3 as a promising bi‐functional medical agent with both MRI contrasting ability and photodynamic therapeutic potential for curing bladder cancer. Abstract : Gadolinium‐based porphyrin complexes, after conjugating with bladder‐cancer‐specific peptides, show both diagnostic and therapeutic effects simultaneously: the complexes have increasing relaxivity after binding with targets and help improve magnetic resonance imaging quality; photodynamic therapy can also be achieved by light trigger and singlet oxygen generation afterward with high selectivity to bladder cancers.